Get started
Viking Therapeutics, Inc.Viking Therapeutics, Inc.Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

VKTX trade ideas

VKTX: Bullish Divergence Leading to a Reversal?Viking Therapeutics has been in a downtrend since late 2024, with price consistently making lower lows. However, since mid January, 2025, both the Relative Strength Index (RSI) and Stochastic Momentum Index (SMI) have been sloping upward, diverging from the price action, which continued to trend lower. IMO, this bullish divergence signals that selling momentum has been weakening despite the stock's decline, and today’s 11.5% spike reinforces the idea that this setup was in play. While a single strong move doesn’t confirm a full trend reversal, the divergence leading up to it suggests that downside pressure has been fading. The key now is whether VKTX can sustain this momentum in the coming sessions. Stay tuned!
NASDAQ:VKTX
by BluntForceOptions
VIKING - To Crash, Or To Explode?VTV Therapeutics (VKTX) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat metabolic diseases. The company primarily targets areas such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, and other metabolic disorders. Here's an in-depth look at the company, its position in the industry, unique aspects, developments, and market potential. As we can see from the above chart, Viking has recently broken the upper channel resistance level and its currently gone in for the re-test to confirm this level as support. However, it appears to be inching back within the channel, signalling a potential break down in price. Industry Overview: Metabolic Disease Therapies The metabolic disease market is a rapidly growing sector, driven by the increasing prevalence of conditions like type 2 diabetes, obesity, NASH, and other liver diseases. The demand for effective treatments in these areas is rising as the global population experiences higher rates of these chronic conditions. NASH, for instance, is a significant focus of research because it can lead to liver cirrhosis and liver cancer, and there are currently limited approved treatments for it. The diabetes and obesity market is also substantial, with new treatments focusing on insulin resistance, fat metabolism, and weight management in high demand. Unique Aspects of VTV Therapeutics (VKTX) 1. Selective Receptor Modulators: [/i ] One of the company’s key differentiators is its use of selective receptor modulators (SRMs), which are designed to specifically target receptors involved in metabolic diseases. This approach allows for potentially more effective treatments with fewer side effects than traditional therapies. 2. Lead Drug Candidate - VTX-800: VTV’s lead candidate is VTX-800, a small molecule selective FFAR4 receptor modulator. This drug is being developed to treat NASH and type 2 diabetes, targeting the free fatty acid receptor 4 (FFAR4), which plays a crucial role in metabolism and insulin sensitivity. In preclinical and early clinical trials, VTX-800 has demonstrated potential for improving both liver function and insulin resistance in patients. 3. Strong Pipeline: In addition to VTX-800, VTV Therapeutics has other promising compounds in its pipeline targeting type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Their approach leverages cutting-edge metabolic biology to address large, underserved markets. 4. Collaborations: The company has also entered into various collaborations with larger biopharmaceutical companies to enhance its research and development capabilities. These partnerships help strengthen its position in the competitive market for metabolic disease therapies. Recent Developments and Trials Phase 2 Clinical Trials: VTX-800 is currently in Phase 2 clinical trials for NASH and type 2 diabetes. The drug has shown promising preclinical results in both liver function and glycemic control, positioning it as a potential breakthrough in these areas. NASH Pipeline: VTV is also pursuing additional treatments for NASH, a field where there is intense competition due to the lack of approved therapies and the growing demand for effective solutions. Type 2 Diabetes Research: Their research on type 2 diabetes involves addressing insulin resistance, a major contributor to the disease. This is a massive market, with increasing incidence globally, creating significant potential for therapies that can effectively manage or reverse the condition. Current Market Cap and Financials As of December 2024, VTV Therapeutics' market cap is approximately $225 million. The company has seen fluctuating stock prices based on clinical trial results and investor sentiment regarding its drug candidates. The small market cap reflects its current stage as a clinical-stage biotech firm, with significant risk and potential rewards as it moves through its clinical trial phases. Potential Future Market Cap The future market cap of VTV Therapeutics will heavily depend on the successful progression and approval of its key drug candidates. If VTX-800 proves to be effective in Phase 3 trials for NASH or type 2 diabetes, the company’s market cap could see a substantial increase, potentially in the $1-2 billion range or higher, similar to other biotech firms that have brought successful metabolic disease drugs to market. 1. NASH Market: The NASH market alone is expected to grow to more than $20 billion by 2025, driven by rising prevalence and lack of treatment options. If VTX-800 is approved for NASH, VTV Therapeutics could capture a significant share of this market, significantly boosting its valuation. 2. Type 2 Diabetes and Obesity : As the prevalence of type 2 diabetes and obesity continues to rise globally, therapies targeting insulin resistance and metabolic function are in high demand. Successful clinical results in these areas could substantially increase VTV Therapeutics’ market cap. Conclusion VTV Therapeutics (VKTX) is a promising player in the metabolic disease space with its innovative approach to targeting diseases like NASH and type 2 diabetes. The company’s progress in clinical trials, particularly with VTX-800, positions it to potentially disrupt the metabolic disease treatment market. While its current market cap reflects the risks associated with being a clinical-stage biotech, the company has significant upside potential, particularly if its leading drug candidate achieves clinical success and gains regulatory
NASDAQ:VKTX
by Who-Is-Caerus
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Next move in progress... This is just my personal trading setup so that I keep it in mind. Viking Therapeutics (VKTX) prepares for its next move. The following things need to happen for me to be bullish: On the 3D chart: 1. The RSI needs to move above the moving average. 2. On the RCI indicator, the mid-trend line (blue) needs to move above the long-trend line (green). 3. The chart needs to break out of its channel to the upside. If so, the next target is around $200. www.barrons.com
NASDAQ:VKTXLong
by ValerianK
Viking Therapeutics Surges 25% Amidst Weight Loss Pill Data In a remarkable turn of events, Viking Therapeutics ( NASDAQ:VKTX ) has sent shockwaves through the pharmaceutical industry with groundbreaking results from its experimental weight loss pill. The company's shares soared by over 25% following the announcement of positive outcomes from a small-scale study, propelling it into the forefront of the fiercely competitive weight-loss drug market. Viking's innovative once-a-day oral tablet demonstrated remarkable efficacy in aiding weight loss among participants. Over 28 days, patients who received the pill experienced an average weight loss of up to 5.3%, significantly surpassing the outcomes of those who were administered a placebo. Notably, an impressive 57% of individuals treated with Viking's pill achieved a weight reduction of at least 5%, showcasing the drug's potential to revolutionize the treatment landscape for obesity. Moreover, the trial unveiled encouraging findings regarding the durability of weight loss, with patients maintaining or even augmenting their progress six days after the cessation of the medication. Viking's CEO, Brian Lian, underscored the significance of this sustained effect, particularly for patients facing challenges in adhering to a daily regimen. "I think that's an encouraging sign that you don't necessarily have to take it every day," remarked Lian during a conference call, hinting at the flexibility and convenience offered by Viking's pioneering approach. Crucially, the trial also provided reassuring insights into the safety and tolerability of the oral drug, with the majority of reported side effects being mild and transient. Unlike some existing treatments, patients did not report vomiting, while gastrointestinal events were predominantly mild in nature—a testament to Viking's commitment to developing a well-tolerated therapy. Analysts have drawn parallels between Viking's weight loss injection and established drugs like Eli Lilly's Zepbound, highlighting their shared mechanism of action in mimicking gut hormones involved in appetite regulation and metabolic control. By leveraging the synergistic effects of GLP-1 and GIP, Viking's pill offers a multifaceted approach to weight management, distinguishing itself in a rapidly evolving landscape. As the company sets its sights on advancing to phase two trials later this year, anticipation is palpable within the investment community and among patients seeking effective and accessible solutions for obesity. With the potential to tap into a burgeoning market projected to reach $100 billion by the end of the decade, Viking Therapeutics ( NASDAQ:VKTX ) stands poised to redefine the standard of care and carve out a niche as a formidable contender in the fight against obesity-related ailments. Technical Outlook Viking Therapeutics ( NASDAQ:VKTX ) Spiked more than 25% prior to the weight loss pill data news with a positive Relative Strength Index (RSI) of 65 indicating a moderately overbought solution with a potential for further surge. In an era marked by escalating rates of obesity and metabolic disorders, Viking's groundbreaking advancements offer a glimmer of hope for millions worldwide, signaling a new dawn in the quest for sustainable weight loss solutions. As the journey unfolds, all eyes remain fixed on Viking Therapeutics, a beacon of innovation and progress in the pursuit of healthier futures.
NASDAQ:VKTXLong
by DEXWireNews
Viking Therapeutics stock jumps 114%Shares of Viking Therapeutics ( NASDAQ:VKTX ) soared more than 114% on Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics ( NASDAQ:VKTX ) is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. But it may not join that space on its own: Analysts have suggested that larger pharmaceutical companies such as Pfizer, which scrapped two of its own weight loss drug candidates last year, could potentially move to acquire a company like Viking Therapeutics. Tuesday's share move puts Viking Therapeutics' market value at roughly $7 billion. The trial followed more than 170 patients with obesity or who are overweight, some of whom received different dose sizes of the injectable drug or a placebo. Those who received weekly doses of the treatment lost up to 14.7% of their body weight from baseline, or 13.1% when adjusted for placebo, after 13 weeks. 88% of patients who received the drug, known as VK2735, achieved at least 10% weight loss, compared with just 4% of those who didn't receive the treatment. Notably, there was no evidence of a plateau in weight reduction at week 13 for any dose of the drug, suggesting that "further weight loss might be achieved" by keeping patients on the treatment longer, Viking CEO Brian Lian said during a call with investors. The drug demonstrated "encouraging" safety in patients following the 13-week trial period. Patients also appeared to tolerate the drug well. Around 4% of patients who received any dose size of the treatment discontinued the study early compared with approximately 6% of those in the placebo group. Viking plans to present the full Phase 2 data at medical conferences. The company also said it plans to meet with the Food and Drug Administration to discuss further steps for the development of VK2735. Separately, the company said it expects to release early stage trial data on an oral version of its weight loss drug. Viking Therapeutics' ( NASDAQ:VKTX ) drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.
NASDAQ:VKTXLong
by DEXWireNews
2
VKTX Stock Soars to Record HighsViking Therapeutics (NASDAQ: NASDAQ:VKTX ) sent shockwaves through the biotech industry as it accelerated its timeline for a groundbreaking obesity treatment, propelling its stock to unprecedented heights. With the prospect of competing head-to-head with pharmaceutical giant Eli Lilly (NYSE: NYSE:LLY ), Viking's innovative approach promises a potential game-changer in the fight against obesity. Viking Therapeutics Surges on Accelerated Timeline In a surprising move, Viking Therapeutics announced an expedited timeline for the release of crucial data regarding its Eli Lilly-rivaling obesity treatment. The biotech firm now anticipates unveiling the results of its midstage trial for its weekly shot ahead of schedule, aligning with the imminent release of data from its oral drug study. Key Catalysts Driving Value: Leerink Partners analyst Thomas Smith underscores the significance of Viking Therapeutics' ( NASDAQ:VKTX ) accelerated catalyst path, citing multiple upcoming data readouts across obesity and NASH. Smith's bullish report emphasizes the potential for significant value inflection in VKTX shares, reflecting growing investor anticipation surrounding the company's groundbreaking developments. Viking's Dual Approach: Daily Pill and Weekly Shot Viking Therapeutics ( NASDAQ:VKTX ) is pioneering a multifaceted approach to combatting obesity, with two distinct treatment modalities in its pipeline. The company's innovative daily pill and weekly shot hold promise for addressing the diverse needs of patients battling weight-related health issues. Eli Lilly-Rivaling Potential: Implications for the Market With Viking Therapeutics ( NASDAQ:VKTX ) poised to challenge Eli Lilly in the obesity treatment arena, the biotech firm's accelerated timeline signifies a potential paradigm shift in the pharmaceutical landscape. As investors digest the implications of Viking's ambitious pursuits, industry watchers anticipate heightened competition and renewed focus on innovative solutions for obesity and related metabolic disorders. Market Response: In response to Viking Therapeutics' ( NASDAQ:VKTX ) groundbreaking updates, NASDAQ:VKTX stock surged by over 15%, reaching an all-time high of $28.10 in morning trades. The remarkable rally underscores investor confidence in the company's strategic vision and the transformative potential of its obesity treatment portfolio. Conclusion: Viking Therapeutics' ( NASDAQ:VKTX ) accelerated timeline for its Eli Lilly-rivaling obesity treatment marks a watershed moment in the biotech industry. As the company advances towards critical data readouts, the market eagerly anticipates the unfolding of a new chapter in the fight against obesity and related metabolic disorders. With NASDAQ:VKTX stock soaring to unprecedented heights, Viking's bold initiatives are poised to reshape the future of healthcare.
NASDAQ:VKTXLong
by DEXWireNews
Viking Therapeutics (VKTX): 30-40%+ Long Trade OpportunityVKTX has suffered a 10%+ decline today and I believe that there is a great long trade setup forming in the buy zone (between the two light blue trendlines). The price action is still bearish at the time of writing so I would monitor the charts for a reversal on lower time frames. However, this will be a quick trade setup for me with an exit at my sell zone between the two yellow trendlines. I believe that this will be a 30-40% trade opportunity depending on where VKTX bottoms out and peaks in these two key zones. I'm seeing a lot of bullish technical analysis signs. The two most notable are the RSI reaching oversold levels and a break below the Bollinger Band. However, I do think that VKTX has a high risk of dropping hard after reaching the yellow trendline so I'm looking to make this a quick trade.
NASDAQ:VKTXLong
by realchartchamp
Seizing Bearish Momentum - Short Trade Idea for VKTX StockHello, traders! Today, I present an intriguing short trade idea for VKTX stock, capitalizing on a market structure shift to the downside. Prepare to ride the bearish wave as we explore the details of this trade opportunity. Trade Overview: We plan to enter the market at $24.14, strategically positioning ourselves after a market structure shift to the downside. This entry point corresponds to a fair value gap, which adds further conviction to our bearish thesis. To safeguard our position, we will set a stop loss at $24.98, ensuring controlled risk management in case of unexpected price movements. Profit Potential: Our take profit target is set at $19.26, indicating the potential for a substantial downside move. This represents a risk-reward ratio of approximately 1 to 5.81, offering an attractive potential return. As VKTX stock navigates lower, we anticipate capitalizing on the bearish momentum and realizing profitable outcomes. Time Horizon: While it is challenging to predict the exact timeframe for achieving our profit target, we anticipate the trade to unfold within a reasonable time horizon. It is essential to monitor the price action closely, adapting our strategy as the market dynamics evolve. Risk Management: As with any trade, managing risk is paramount. We have carefully chosen our stop loss at $24.98 to limit potential losses. This level has been selected based on technical analysis and consideration of VKTX stock's recent price behavior. Remember to always prioritize risk management and adhere to your risk tolerance. Please note that trading involves risks, and this trade idea is for educational purposes only. It is crucial to conduct your own analysis, consider your risk tolerance, and, if needed, seek advice from qualified professionals before making any trading decisions. Embark on this short trade journey for VKTX stock with careful consideration and disciplined execution. Market structure shifts can provide unique opportunities, and by aligning ourselves with the bearish momentum, we aim to capitalize on potential downside movements. Disclaimer: The trade idea provided here is for educational purposes only and should not be considered as financial advice. Trade at your own risk, and exercise caution in your decision-making process.
NASDAQ:VKTXShort
by yura_trades
1
Momentum Stock: Viking TherapeuticsViking Therapeutics Inc is a clinical-stage biopharmaceutical company and is focused on the development of therapies designed to treat metabolic and endocrine disorders. This includes conditions like fatty liver disease and type 2 diabetes, which have been on the rise globally. The stock's price performance has been quite remarkable in recent periods. The share price has shown a steady increase over different timescales, with particularly impressive growth over the past six months and one year, seeing a 499.75% and 945.06% surge respectively. The year to date growth is at 164.96%, showcasing a persistent bullish trend for Viking Therapeutics. The Relative Strength Index (RSI) of 65 indicates that the stock is currently close to the overbought territory, suggesting a strong momentum in the stock's price. It also hints at potential future price corrections, which is common after periods of rapid growth. However, investors may want to approach this stock with caution despite its impressive performance. Biotech stocks like VKTX can be quite volatile due to the binary nature of clinical trials results. Positive outcomes can result in significant stock price appreciations, as we might be seeing here. On the other hand, a failed clinical trial can drastically affect the stock price in the opposite direction. Moreover, Viking Therapeutics, as a clinical-stage company, likely doesn't have a product on the market yet, meaning it probably doesn't have revenue or profit to fall back on. This can be a point of concern as it makes the stock's performance heavily reliant on the successful development and subsequent approval of its therapies. Stocks like this are HIGHLY speculative and trying to time any kind of an entry can be difficult. It has just had a 10% pull back and regained most of it quite quickly. It could continue to run, who knows. If you decide to trade it, keep a close eye on it. A trailing stop loss of around 15% would have kept you in most of this trade. If it broke below that it could have been a good sign to exit and look for a new entry when the trend resumed. As always how you interpret and decide to act on any results is up to you. This is just data not financial or trading advice and past performance is in no way any guarantee of future performance. Think of it as a way to spot stocks you might be interested in and can add to your watch list and perform further research on and or discuss with your broker. Again. Not trading advice . Industries and companies change. Trends can end. Do your own research / discuss it with your advisor, but might be one to watch.
NASDAQ:VKTX
by zAngus
6
Watchlist 2023-03-28 $SPY $BABA $VKTX $AUPHSPY - unable to hold the reversal from yesterday for a fairly range bound day, gapping down to PD lows but also PPD support at 395.50. Note that SPY once again rejected the important 399 level right off the open, this is a sign to me that the market needs to head lower. Home price numbers have been the stickiest form of inflation so when that data is released at 9:00 that could provide a catalyst for the direction of the market if it comes in hot, if it does, we could see at least 394 support tested. Remember, for a trend day we'll need to see the $ADD pinned near +\-2000 and $VOLD ratio over +/- 3 and $TICK cumulating past 0 wicking to +/-900. $BABA - Alibaba to Split Into Six Separate Groups in Biggest Shake! Extremely big news. Gapping up 9% for2.5 ATR move. Chinese ADRs can be tricky to trade. Like crypto. They can have huge rallies and complete reversals so it's important to take profits when you have them. Currently at 95 resistance,, nest is 97 200 EMA, and they 100. Buying dips on the name looking for a push higher early on. Scaling into the trade as more sign of continued strength persist. If it gets above 95 early on and reverses back into the channel that is an exit signal. $VKTX - Viking Therapeutics obesity drug shows promise in early-stage study. VKTX has a history of gapping 'bigly' and going EVN further. This is as potentially A+ trade as it's gapping over the insanely flat and key 12 top resistance. PM resistance at 12.5 is next. With no res until 23 ATH. ATR is only .75 so it's gapping up 5, which is usually excessive but not for this name. LLY has a similar Obesity drug and this name is up 37% since 2022. Watch the tap closely for sign of buyers (wicks, lower highs, strong green bars and sequential red bars) Looking at add a starter at support, adding on continued signs of strength, and consolidation break of the 14.50 if all signs align. Other watches: $GOLD - gapping to the 18.70 key pivot. A bit extended into the open but signs of weakness in the SPY could move this higher, uncertainly in the market also helps. Support near 18.50, 18.40. Other watches: $VMW - gap and go support at 121 after a beautiful BO. $AUPH - looking for support test of 10.65 or 10.40
NASDAQ:VKTXLong
by UnclePennybagss